BRAIN Biotech AG: First Development Phase for a novel Genome Editing Tool Completed (CRISPR Cas)

BRAIN Biotech AG: First Development Phase for a novel Genome Editing Tool Completed (CRISPR Cas)

Zwingenberg, Germany
May 6^th, 2021

BRAIN Biotech AG ('BRAIN') has successfully completed the first development phase for a novel genome editing tool based on a Non-Cas9 nuclease. It has been validated as a genome editing tool and the tool has been demonstrating DNA targeting activity in selected bacteria, fungi and yeast. Activity in plants has been achieved but still needs to be validated. Further potential beyond selected microorganisms and plants is currently being explored. A first IP application to protect the nuclease sequence was submitted. The tool is expected to give BRAIN freedom to operate for internal as well as customer projects and could provide significant economic upside from commercializing the technology if the next development steps prove to be successful and a patent is granted.

Notifying person:

Michael Schneiders, Head of IR & Sustainability

BRAIN Biotech AG
Darmstädter Str. 34-36, 64673 Zwingenberg, Germany
www.brain-biotech.com

Investor Relations Office
Tel.: [phone]
Fax: [phone]
E-Mail: [e-mail]